BJMO - , issue ,
S. Bulteel , T. Muilwijk MD
SUMMARY
Intravesical BCG is the standard of care in the treatment of high-risk non-muscle invasive bladder cancer as it decreases the risk of recurrence and progression. Although it has been used for more than 40 years, it is currently still superior over chemotherapy and other immunotherapies. The worldwide shortage of BCG stresses the need for alternatives of BCG, for which the only curative treatment option outside clinical studies is an early radical cystectomy.
Read more
BJMO - volume 11, issue 1, february 2017
T. Muilwijk MD, T. Adams MD, G. Witters MD, H. Vandeursen MD, PhD
SUMMARY
Robot-assisted radical prostatectomy has become standard-of-care in most centres of excellence in the treatment of prostate cancer. Recent literature shows a reduced complication risk, reduced transfusion need, shorter hospitalisation and functional and oncological benefit in comparison with open radical prostatectomy. Long term follow-up data and large randomised clinical trails are currently lacking.
(BELG J MED ONCOL 2017;11(1):4–6)
Read more
Top
